Literature DB >> 11872042

Cisplatin-induced in vivo differentiation of human embryonal carcinoma.

Y Mizutani1, N Sato, A Kawauchi, N Nonomura, M Fukushima, T Miki.   

Abstract

OBJECTIVE: To investigate the differentiation of embryonal carcinoma (EC) by cisplatin, and the underlying mechanism, as untreated metastases of nonseminomatous germ cell tumours rarely consist of fully differentiated mature somatic tissues, but such mature metastases are more common after various treatments, including chemotherapy.
MATERIALS AND METHODS: The TTSC-3 human testicular EC line heterotransplanted into nude mice was used as a target. After treating tumour-bearing mice with intraperitoneal injections of varying doses of cisplatin, the histopathology of the tumours was assessed and various gene expressions in the tumours determined by cDNA-array technology.
RESULTS: When cisplatin at 1 mg/kg/week was injected intraperitoneally into TTSC-3-bearing mice, there was no effect on tumour growth. However, injecting cisplatin at 5 mg/kg/week induced a marked regression of the tumour. In contrast, cisplatin at 3 mg/kg/week had a modest inhibitory effect on tumour growth and induced tumour dormancy. Histological examination showed that 5 weeks after injecting cisplatin (3 mg/kg/week), primitive mesenchymal-like cells increased, and 10 weeks afterward cartilage and well-developed glands (teratoma) were apparent; at > 15 weeks afterward there were no EC cells visible. cDNA probes from reverse-transcribed mRNAs of TTSC-3 treated with cisplatin or saline for 10 weeks were compared to identify genes differentially expressed in cisplatin-treated TTSC-3. Of 1176 different human cDNA transcripts in cisplatin-treated TTSC-3, three genes (tumour necrosis factor receptor 1, caspase 8 and Apaf1), which are associated with apoptosis, were expressed markedly more than after saline injection.
CONCLUSIONS: The intermediate dose of cisplatin inhibited tumour growth of EC by inducing differentiation and enhancing apoptosis-related gene expression. These findings suggest that cisplatin may play a significant role in the differentiation of EC in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872042     DOI: 10.1046/j.1464-4096.2001.01794.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

1.  αvβ3 imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study.

Authors:  Nicolas Aide; Mélanie Briand; Pierre Bohn; Soizic Dutoit; Charline Lasnon; Jacques Chasle; Jean Rouvet; Romain Modzelewski; Antony Vela; Edwiges Deslandes; Pierre Vera; Laurent Poulain; Franck Carreiras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-30       Impact factor: 9.236

Review 2.  Physiological and pathological roles of Apaf1 and the apoptosome.

Authors:  E Ferraro; M Corvaro; F Cecconi
Journal:  J Cell Mol Med       Date:  2003 Jan-Mar       Impact factor: 5.310

3.  Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.

Authors:  Jason C Hall; Laura A Marlow; Adam C Mathias; Louis K Dawson; William F Durham; Kenneth A Meshaw; Robert J Mullin; Aidan J Synnott; Daniel L Small; Murli Krishna; Daniel von Hoff; Julia Schüler; Steven N Hart; Fergus J Couch; Gerardo Colon-Otero; John A Copland
Journal:  J Transl Med       Date:  2016-05-10       Impact factor: 5.531

4.  Cisplatin induces differentiation in teratomas derived from pluripotent stem cells.

Authors:  Atsushi Kurata; Masakatsu Takanashi; Shin-Ichiro Ohno; Koji Fujita; Masahiko Kuroda
Journal:  Regen Ther       Date:  2021-06-08       Impact factor: 3.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.